Connect with us

Spread & Containment

ACME Lithium

Key Projects in the Epicenter of US Lithium Development, Nevada’s Clayton Valley
The post ACME Lithium appeared first on Investing News Network.

Published

on

This ACME Lithium profile is part of a paid investor education campaign.*

Overview

The large-scale shift to carbon-pollution-free electricity and net-zero emissions is already underway. According to analysts and industry executives, “the pandemic has proved to be a reset point for the market.” With the worldwide lithium battery market expected to grow exponentially in the coming decade — which has the potential to reach a record value of US$80 billion by 2026 — it’s clear there is significant potential and a lot of growth to come.

“And when you come into this growth period where year-on-year the volumes are getting significantly bigger in terms of orders from the battery industry, I think that has the potential to create a real bottleneck in terms of keeping supply up with demand,” said Andrew Miller, product director at Benchmark Mineral Intelligence in an interview with INN.

Add to that the passing of the Paris Agreement in 2016 and the Biden Administration’s energy and infrastructure plans, and it points to an increased focus on combating the climate crisis in governments around the world. Even the US Department of Energy (DOE) revealed it believes the solution requires establishing a domestic supply chain for lithium-based batteries.

But with limited production capacity available in the United States, more production will be required to facilitate the growing needs of the electric vehicle and stationary grid storage markets. It’s this perfect storm of conditions that have led Clayton Valley in Esmeralda County, Nevada to become a hotspot for lithium exploration and development in the US. This region uniquely hosts the only US-based lithium mine.

ACME Lithium Inc. (CSE:ACME,OTC:ACLHF) is a junior mineral exploration and development company focused on acquiring and developing a portfolio of exploration-stage, lithium-containing projects in Nevada. The company’s management team is highly experienced with a strong history of success in building and financing resource companies around the world including the development of lithium-based projects.

ACME Lithium currently operates its Clayton Valley and Fish Lake Valley projects in the mining-friendly Esmeralda County area in Nevada. The properties are strategically located near Albemarle Corporation’s Silver Peak Lithium mine. The Silver Peak lithium mine has continuously produced lithium since 1966, with concentrations as high as +1,000 ppm of lithium.

ACME Lithium’s projects are also located in an area with a developing battery supply chain, including Tesla’s Gigafactory, which sits only 200 miles away. Both of ACME Lithium’s properties have year-round access to expertise, infrastructure, rail and roads, power and water, including favorable weather conditions and logistics.

“We have been working on our exploration plan over the last few months in preparation for what’s going to be a busy summer. We actually have geological targets that are ready to drill test. We’re going to do some additional mapping and sampling of both the Fish Lake Valley project as well as geophysical analysis of our project in Clayton Valley and we hope to drill before year-end on both projects assuming we get the results we’re looking for from the preliminary work. We also continue to look at accretive projects around the globe,” said ACME Lithium CEO Steve  Hanson.

The Clayton Valley property has the potential to host lithium brine just like the Silver Peak Lithium mine, while the Fish Lake Valley property has been confirmed to host the same geological processes like those found at the Albemarle mine in Clayton Valley. The presence of lithium brine would provide ACME Lithium with a strong competitive advantage against other companies that typically go after clays or hard rocks. Clay and hard rocks are more difficult to process and create a concentrator product that can be used by technology companies in battery production. The company strongly believes that its properties have the potential to produce lithium under simple metallurgical conditions based on preliminary indications.

In July 2021, the company closed its second and final tranche of oversubscribed non-brokered private placement financing of units at C$2,378,650 at a price of C$0.40 per unit for total gross proceeds of C$3,609,666.80. The company intends to use the proceeds to partly fund exploration on its lithium projects in Nevada for 2021 and general working capital. ACME Lithium is capitalized and aiming to acquire and develop additional projects in the lithium sector and growing electric vehicle sector for 2021 and 2022 to increase shareholder value.

ACME Lithium owns and is under the option to acquire a combined 100% interest in 122 claims totalling 2,440 acres in Clayton Valley. The company also owns 100% interest in 81 lode mining claims totalling 1,620 acres in Fish Lake Valley.

The company’s leadership team has decades of experience in the mining, energy and finance sectors. ACME Lithium also boasts multiple notable industry figures, including Yiannis Tsitos, who has worked for the BHP Billiton group, William Feyerabend, who has direct experience in developing lithium projects and Steve Hanson, who has been involved in multiple successful M&A transactions in the mining and resource sector, including exit strategies with major corporations.

ACME Lithium’s Company Highlights

  • ACME Lithium (CSE:ACME,OTC:ACLHF) is a junior mineral exploration and development company focused on acquiring and developing a portfolio of exploration-stage lithium-based properties in Nevada.
  • The company’s Clayton Valley and Fish Lake Valley projects are located in the mining-friendly area of Esmeralda County in Nevada. Both properties have year-round access to expertise, infrastructure, rail and roads, power and water including favorable weather conditions and logistics.
  • Clayton Valley and Fish Lake Valley are strategically located near Albemarle Corporation’s lithium-producing Silver Peak mine with Clayton Valley potentially hosting the same lithium brine found at Silver Peak.
  • ACME Lithium owns and is under the option to acquire a combined 100% interest in 122 claims totalling 2,440 acres in Clayton Valley and owns 100% interest in 81 lode mining claims totalling 1,620 acres in Fish Lake Valley.
  • The company plans to begin drilling before the end of 2021 on both projects after additional exploration, including mapping, sampling and geological testing.
  • The company’s management team is highly experienced with a strong history of success in building and financing resource companies around the world including the development of lithium-based projects.

ACME Lithium’s Key Projects

Clayton Valley Project

The Clayton Valley project is located 190 miles northwest of the city of Las Vegas in Esmeralda County in Nevada. The property spans 2,440 acres with year-round access to expertise, infrastructure, rail and roads, power and water including favorable weather conditions and logistics. Clayton Valley is located directly to the south of Albemarle Corporation’s Silver Peaks lithium mine that has produced lithium minerals from brines continuously since 1966 including samples as high as 228 ppm lithium. Concentrations up to +1,000 ppm have also been found to occur within specific horizons of fine sediments.

ACME Lithium’s claims on the Clayton Valley project cover basin-fill sediments and aquifers similar to the sediments currently producing brines in the region based on historic drill information and geophysical survey results. There is also promising evidence that the extensive valley growth faults provide an adequate plumbing system to foster brine reservoir accumulation for moving fluids around.

ACME Lithium owns and is under the option to acquire a combined 100% interest in 122 claims including the CC, CCP, JR, and SX Placer claims on the Clayton Valley property. Moving forward, the company plans to continue interpreting geophysical survey data and results as well as develop its drill targets to test indicated and prospective aquifers. The company believes it has the potential to host lithium brines sourced from lithium Tertiary clays accumulated in a basin environment similar to the Silver Peak lithium mine.

Fish Lake Valley

The Fish Lake Valley project is located in Esmeralda County in Nevada. The project spans 1,620 acres with year-round access to expertise, infrastructure, rail and roads, power and water including favorable weather conditions and logistics. Fish Lake Valley is located 24 miles northwest of Albemarle Corporation’s Silver Peak’s lithium mine that has produced lithium minerals from brines continuously since 1966. Concentrations up to +1,000 ppm have been found to occur within specific horizons of fine sediments and the Silver Peak mine includes samples as high as 228 ppm.

Exploration at Fish Lake Valley since 2010 has revealed sites with anomalous lithium values greater than 100 ppm in Tertiary claystone, sediment samples with values approaching 600 ppm lithium in claystone, positive geophysical surveys and lithium within clay-rich horizons. In 2016, initial mapping and sampling completed by the previous operator found lithium values with potentially the same process as at Clayton Valley ranging from 5 to 40 ppm in mudstones. In 2018, the previous operator confirmed that it was, in fact, the same geological process resulting in high lithium values in fine sediments found at the Fish Lake Valley property.

ACME Lithium owns 100% interest in 81 lode mining claims on the property. The company is currently in the process of designing drill testing of lithium claystone to determine the economic potential. Beginning in the third quarter of 2021, the company plans to begin to identify new targets and expand exploration of the property through in-depth mapping, sampling, and geophysics tests.

ACME Lithium’s Management Team

Steve Hanson — Director, President, and CEO

Stephen Hanson has over 28 years of finance and corporate development experience across four continents. Hanson has held executive (CEO), board and advisor positions for numerous private and public companies in mining, alternative energy, oil and gas sectors. Hanson has been involved in a number of successful M&A transactions including exit strategies with major corporations.

Yannis Tsitos — Director

Yannis Tsitos is originally a physicist-geophysicist with nearly 30 years of experience in the mining industry, including 19 years with BHP Billiton group which is one of the biggest mining companies in the world. Tsitos is currently the President of Goldsource Mines Inc., a TSXV-listed company, and sits on several boards as an independent director.

William Feyerabend — VP Exploration

William Feyerabend is a Certified Professional Geologist and a member of the American Institute of Professional Geologists with direct working experience in the exploration and development of lithium projects, including technical reports in Nevada. Feyerabend has worked on projects in the American West, Mexico and South America.

Vivian Katsuris — Director

Vivian Katsuris is a specialist in corporate development, management, consulting, and corporate services. Katsuris has over 28 years of financial experience in the brokerage industry, the North American capital markets and public financings. Katsuris holds director and officer positions with several CSE- and TSXV-listed companies.

Zara Kanji — Chief Financial Officer, and Corporate Secretary

Zara Kanji is experienced in financial reporting compliance for junior listed companies, taxation, general accounting, financial reporting and value-added advisory services for individuals, private and public companies. Kanji is a member of the Chartered Professional Accountants of BC and Canada.


*Disclaimer: This profile is sponsored by ACME Lithium (CSE:ACME). This profile provides information that was sourced by the Investing News Network (INN) and approved by ACME Lithium, in order to help investors learn more about the company. ACME Lithium is a client of INN. The company’s campaign fees pay for INN to create and update this profile.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with ACME Lithium and seek advice from a qualified investment advisor.

The post ACME Lithium appeared first on Investing News Network.

Read More

Continue Reading

Spread & Containment

China Suspends Travel, Ramps Up Testing As Delta Outbreak Hits Wuhan

China Suspends Travel, Ramps Up Testing As Delta Outbreak Hits Wuhan

China’s worst outbreak since COVID first emerged in the city of Wuhan has continued to spread, prompting authorities to intensify their efforts to crush the delta-driven…

Published

on

China Suspends Travel, Ramps Up Testing As Delta Outbreak Hits Wuhan

China's worst outbreak since COVID first emerged in the city of Wuhan has continued to spread, prompting authorities to intensify their efforts to crush the delta-driven outbreak. However, as the virus continues to elude their grasp, it's looking increasingly likely that Beijing's "zero tolerance" approach might hamstring economic growth, as analysts from Goldman Sachs warned in a recent note to clients.

More than 2 dozen cities have counted more than 300 cases over the past few weeks as the number of cases has quickly multiplied. China now has 144 medium- and high-risk areas - the most since the initial outbreak in early 2020, according to the National Health Commission.

By Monday, all of China's 31 provincial-level jurisdictions had issued notices by Monday advising people not to travel domestically. Some provincial governments singled out only medium- and high-risk regions, while others asked people to avoid all inter-provincial travel. According to the SCMP, Beijing's "zero-tolerance" approach to fighting COVID, which remains minimal compared with China's vast population, has "scared away" the tourists.

China reported 71 new COVID cases from local transmission on Wednesday, more than half of them in coastal Jiangsu province near the epicenter of Nanjiang, AP reported.

The CCP has decided to expand travel restrictions on Wednesday: ride-hailing services and public transit have been suspended in all medium- to high-risk areas. Immigration authorities have promised to "strictly restrict non-urgent, unnecessary cross-boarder travel" including restricting the issuing of passports for Chinese citizens. To try and stifle the virus before it has an opportunity to take hold, the city ordered millions of residents to undergo mandatory testing, leading to lines forming across the city. The city has also closed 17 bus lines and a handful of subway stations. Cases have been confirmed in 17 provinces and some two dozen cities, including Wuhan, which reported a handful of cases this week, per CNN.

Fears of another crushing lockdown - many Wuhan residents still have PTSD from the 70-day+ lockdown in the city that was used to crush the original outbreak, at a tremendous cost to the city's residents mental and physical health. Videos and photos shared on social media have shown empty shelves and long lines at supermarkets, as residents scramble to stock up on supplies.

"Seeing Wuhan people panic buying at supermarkets makes me feel sad. Only those who have experienced it understand how terrible it is, (we) dread a return to the days of staying at home and not knowing where the next meal is," said one Wuhan resident on Weibo.

The present outbreak began a little over a week ago in Nanjing, a city in Jiangsu province in eastern China, where nine airport cleaners were found to be infected on July 20 during a routine test. Chinese authorities have blamed the cluster on workers from Russia, who arrived at the Nanjing Lukou International Airport on July 10.

"It is believed that the cleaners did not strictly follow anti-epidemic guidelines after cleaning Flight CA910 and contracted the virus as a result. The infection further spread to other colleagues, who are also responsible for cleaning and transporting garbage on both international and domestic flights," reported state news agency Xinhua.

Given the provenance of the latest outbreak, Beijing has committed to ramp up testing of transport workers around the country. Workers at ports and borders considered high risk will be tested for the virus every other day said Li Huaqiang, a senior official with Ministry of Transport.

Earlier this week, another COVID-19 hotspot was identified in the city of Zhangjiajie, near a scenic area famous for sandstone cliffs, caves, forests and waterfalls.

Despite only confirming some 19 cases over the past week, the city ordered residential communities sealed Sunday, preventing people from leaving their homes. In a subsequent order on Tuesday, officials said no residents, and no tourists, would be allowed to leave the city. On Wednesday, the city government's Communist Party disciplinary committee issued a list of local officials who "had a negative impact" on pandemic prevention and control work who would be punished.

Far higher numbers were reported in Yangzhou, a city next to Nanjing, which has recorded 126 cases as of Tuesday. As a result, all cross-city ferry services, water tours were suspended in eastern Yangzhou on Wednesday.

But most alarmingly, the outbreak has already touched Beijing, eve though it's thousands of miles removed from the epicenter in Nanjiang. On Wednesday, 7 cases were confirmed in the capital city, prompting authorities to lock down two residential compounds.

As of this wee, China has doled out more than 1.71 billion vaccine doses to its population of 1.4 billion. Officials say 40% of the population is fully vaccinated, but the outbreak is also raising questions about the efficacy of those vaccines.

Tyler Durden Wed, 08/04/2021 - 18:00

Read More

Continue Reading

Government

Broward County Public Schools “Pause” Proposed Mask Mandate After DeSantis Threatens To Cut Funding

Broward County Public Schools "Pause" Proposed Mask Mandate After DeSantis Threatens To Cut Funding

Update: Broward County schools on Aug. 3 again changed course on whether to comply with or defy an executive order by Republican Gov. Ron…

Published

on

Broward County Public Schools "Pause" Proposed Mask Mandate After DeSantis Threatens To Cut Funding

Update: Broward County schools on Aug. 3 again changed course on whether to comply with or defy an executive order by Republican Gov. Ron DeSantis which prohibited schools from imposing mask mandates on students.

In a written statement to The Epoch Times, the school board has not changed its policy but “paused it.”

“In light of the governor’s executive order, the district is awaiting further guidance before rendering a decision on the mask mandate for the upcoming school year. At this time, the district’s face covering policy, which requires the use of masks in district schools and facilities, remains in place.”

The School Board plans to discuss next steps at a special meeting on August 10.

Dr. Vickie Cartwright, interim superintendent of Broward County schools is looking into the executive order further.

“The school board is reviewing information and looking for language from our executive rules as a result of the governor’s executive order,” Cartwright said in a video statement.

On July 30, the governor signed an executive order that protects parents’ right to make decisions regarding the masking of their children as a means of protecting them from COVID-19. A month earlier, he signed a bill that protected the parents’ “fundamental right” to make decisions for the upbringing, education, health care, or mental health of their minor children.

“Many Florida schoolchildren have suffered under forced masking policies, and it is prudent to protect the ability of parents to make decisions regarding the wearing of masks by their children,” DeSantis said.

*  *  *

As we detailed earlier, Florida Governor Ron DeSantis has had enough of the Covid hysteria.

Aside from going on record and calling the lockdowns a "huge mistake" back in April of his year, DeSantis has done everything he can to try and turn over the power in his state to its citizens, and away from the government.

The latest example of this comes this week, where DeSantis stood down Florida's second largest school district that was attempting to impose a mask mandate. In response, DeSantis threatened to withhold funding from the district. 

"Broward County Public Schools announced last week that it would require mask use after the CDC issued new guidance recommending universal indoor masking for all teachers, staff, students and visitors to K-12 schools this incoming school year, regardless of vaccination status," Axios reported this week.

DeSantis had issued an executive order last Friday barring schools from requiring masks when school re-opens next month. His order read that "if the State Board of Education determines that a district school board is unwilling or unable to comply with the law, the State Board shall have the authority to, among other things, withhold the transfer of state funds, discretionary grant funds ... and declare the school district ineligible for competitive grants."

And that's exactly what DeSantis threatened to do before Broward County Public Schools backed down, releasing a statement on Monday that said: "Broward County Public Schools intends to comply with the governor's latest executive order."

The statement continued: "Safety remains our highest priority. The district will advocate for all eligible students and staff to receive vaccines and strongly encourage masks to be worn by everyone in schools."

DeSantis also spoke at a press conference this week, stating: “Even among a lot of positive tests, you are seeing much less mortality that you did year-over-year. Would I rather have 5,000 cases among 20-year-olds or 500 cases among seniors? I would rather have the younger.”

“We are not shutting down. We are going to have schools open. We are protecting every Floridian’s job in this state. We are protecting people’s small businesses. These interventions have failed time and time again throughout this pandemic, not just in the United States but abroad.”

As we noted back in April, DeSantis told The Epoch Times that the lockdowns were a “huge mistake,” including in his own state.

“We wanted to mitigate the damage. Now, in hindsight, the 15 days to slow the spread and the 30—it didn’t work,” DeSantis said.

“We shouldn’t have gone down that road.”

Florida’s lockdown order was notably less strict than some of the stay-at-home measures imposed in other states. Recreational activities like walking, biking, golf, and beachgoing were exempted while essential businesses were broadly defined.

“Our economy kept going,” DeSantis said. “It was much different than what you saw in some of those lockdown states.”

DeSantis has also opposed vaccine passports in Florida. 

Tyler Durden Wed, 08/04/2021 - 22:40

Read More

Continue Reading

Spread & Containment

‘For $1/Day’… Double-Blind Ivermectin Study Reveals COVID Patients Recover More Quickly, Are Less Infectious

‘For $1/Day’… Double-Blind Ivermectin Study Reveals COVID Patients Recover More Quickly, Are Less Infectious

A double-blind Israeli study has concluded that Ivermectin, an inexpensive anti-parasitic widely used since 1981, reduces both…

Published

on

'For $1/Day'... Double-Blind Ivermectin Study Reveals COVID Patients Recover More Quickly, Are Less Infectious

A double-blind Israeli study has concluded that Ivermectin, an inexpensive anti-parasitic widely used since 1981, reduces both the duration and infectiousness of Covid-19, according to the Jerusalem Post.

The study, conducted by Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center in Tel Hashomer, looked at some 89 eligible volunteers over the age of 18 who had tested positive for coronavirus, and were living in state-run Covid-19 hotels. After being divided into two groups, 50% received ivermectin, and 50% received a placebo. Each patient was given the drug for three days in a row, an hour before eating.

83% of participants were symptomatic at recruitment. 13.5% of patients had comorbidities of cardiovascular disease, diabetes, chronic respiratory disease, hypertension or cancer. The median age of the patients was 35, ranging from 20 to 71-years-old.

Results

Treatment was discontinued on the third day, and patients were monitored every two days thereafter. By day six, 72% of those treated with ivermectin tested negative for the virus, vs. 50% of those who received the placebo. Meanwhile, just 13% of ivermectin patients were able to infect others after six days compared to 50% of the placebo group - nearly four times as many.

Hospitalizations

Three patients in the placebo group were admitted to hospitals for respiratory symptoms, while one ivermectin patient was hospitalized for shortness of breath the day the study began - only to be discharged a day later and "sent back to the hotel in good condition," according to the study.

"Our study shows first and foremost that ivermectin has antiviral activity," said Schwartz, adding "It also shows that there is almost a 100% chance that a person will be noninfectious in four to six days, which could lead to shortening isolation time for these people. This could have a huge economic and social impact."

The study, which appeared on the MedRxiv preprint server and has not yet been peer-reviewed. That said, Schwartz pointed out that similar studies - 'though not all of them conducted to the same double-blind and placebo standards as his' - also showed favorable results for the drug.

Ivermectin is incredibly cheap due to its widespread use across the world to treat malaria, scabies, lice and other parasitic infections. In Bangladesh, the cost of ivermectin is around $0.60 to $1.80 for a five-day course, according to the report. In Israel, it costs up to $10 per day.

While Schwartz's study showed efficacy among those who had already tested positive, it didn't determine whether ivermectin is an effective prophylactic which could prevent one from contracting Covid-19, nor does it show whether it reduces chances of hospitalization - however Schwartz noted that other studies have shown such evidence.

For example, the study published earlier this year in the American Journal of Therapeutics highlighted that “a review by the Front Line COVID-19 Critical Care Alliance summarized findings from 27 studies on the effects of ivermectin for the prevention and treatment of COVID-19 infection, concluding that ivermectin ‘demonstrates a strong signal of therapeutic efficacy’ against COVID-19.”

“Another recent review found that ivermectin reduced deaths by 75%,” the report said. -Jerusalem Post

As the Post notes, Ivermectin has been actively opposed as a Covid treatment by the World Health Organization, the FDA, and pharmaceutical companies.

The “FDA has not approved ivermectin for use in treating or preventing COVID-19 in humans,” it said.

“Ivermectin tablets are approved at very specific doses for some parasitic worms, and there are topical (on the skin) formulations for head lice and skin conditions like rosacea. Ivermectin is not an antiviral (a drug for treating viruses). Taking large doses of this drug is dangerous and can cause serious harm.”

Mere discussion of the drug has resulted in big-tech censoring or deplatforming thought leaders in collaboration with the Biden administration.

Meanwhile, Merck Co. - which manufactured the drug in the 1980s, has come out big against the use of ivermectin to treat Covid-19. In February, the company's website read: "Company scientists continue to carefully examine the findings of all available and emerging studies of Ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that, to date, our analysis has identified no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies; no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and a concerning lack of safety data in the majority of studies."

As the Post points out - Merck has not launched a single study of its own on ivermectin.

"You would think Merck would be happy to hear that ivermectin might be helpful to corona patients and try to study it, but they are most loudly declaring the drug should not be used," said Schwartz.

"A billion people took it. They gave it to them. It’s a real shame."

In closing, the research team writes that "Developing new medications can take years; therefore, identifying existing drugs that can be re-purposed against COVID-19 [and] that already have an established safety profile through decades of use could play a critical role in suppressing or even ending the SARS-CoV-2 pandemic."

"Using re-purposed medications may be especially important because it could take months, possibly years, for much of the world’s population to get vaccinated, particularly among low- to middle-income populations."

Tyler Durden Wed, 08/04/2021 - 18:55

Read More

Continue Reading

Trending